Brown Michael Jon Sells Shares of DexCom, Inc. $DXCM

Editorial illustration for DexCom, Inc. (DXCM)

Key Points

  • Brown Michael Jon sold 1,700 shares of DexCom, Inc. ($DXCM) worth $128,435.
  • $DXCM last traded around $73.16.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Brown Michael Jon, EVP Chief Legal Compliance Off at DexCom, Inc. ($DXCM), sold 1,700 shares at an average price of $75.55, for a total transaction of $128,435. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom, Inc. Stock Down 19.4%

Shares of DexCom, Inc. ($DXCM) traded around $73.16 on Wednesday, down 19.4% for the day.

Last price$73.16
Market cap$34.36B
P/E ratio35.85
Forward P/E29.15
PEG ratio1.68
Beta1.41
52-week low$54.11
52-week high$92.59
50-day MA$79.60
200-day MA$70.29
Current ratio1.73
Quick ratio1.37
Debt-to-equity0.53

DexCom, Inc. Earnings

EPS (ttm)$2.54
Revenue (ttm)$4.97B
Revenue growth13.10%
Net margin20.12%
Return on equity38.49%
Next earningsOct 29, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$94.12
High target$115
Low target$79
Analysts covering25

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

ExchangeNasdaqGS
SectorHealthcare
IndustryMedical Devices
HeadquartersSan Diego, CA
CEOMr. Jacob Steven Leach
Employees11,000

Get DexCom, Inc. alerts

New 13F filings, insider trades, and analyst moves on $DXCM, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.